This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Motus GI Holdings Croissance future

Future contrôle des critères 2/6

Motus GI Holdings devrait augmenter ses bénéfices et ses revenus de 19.3% et de 142.2% par an respectivement, tandis que le BPA devrait croître de croître de 65.9% par an.

Informations clés

19.3%

Taux de croissance des bénéfices

65.9%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	14.7%
Taux de croissance des recettes	142.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	22 Nov 2023

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:7M4 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2024	2	-11	N/A	N/A	2
12/31/2023	0	-13	N/A	N/A	2
9/30/2023	0	-14	-13	-13	N/A
6/30/2023	1	-16	-15	-15	N/A
3/31/2023	1	-18	-17	-17	N/A
12/31/2022	1	-19	-18	-17	N/A
9/30/2022	1	-20	-18	-17	N/A
6/30/2022	0	-20	-17	-17	N/A
3/31/2022	0	-19	-15	-15	N/A
12/31/2021	0	-25	-15	-14	N/A
9/30/2021	0	-25	-14	-13	N/A
6/30/2021	0	-24	-13	-13	N/A
3/31/2021	0	-24	-15	-14	N/A
12/31/2020	0	-19	-17	-17	N/A
9/30/2020	0	-21	-20	-20	N/A
6/30/2020	0	-22	-22	-21	N/A
3/31/2020	0	-23	-22	-22	N/A
12/31/2019	0	-23	-20	-20	N/A
9/30/2019	0	-23	-20	-19	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	0	-21	-18	-17	N/A
12/31/2018	0	-22	-15	-15	N/A
9/30/2018	0	-20	-14	-13	N/A
6/30/2018	0	-18	-13	-13	N/A
3/31/2018	0	-18	-12	-12	N/A
12/31/2017	N/A	-13	-11	-10	N/A
9/30/2017	N/A	-12	-10	-10	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-7	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 7M4 devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 7M4 devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 7M4 devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 7M4 ( 142.2% par an) devrait croître plus rapidement que le marché German ( 5.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 7M4 ( 142.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 7M4 devrait être élevé dans 3 ans

This company listing is no longer active

Motus GI Holdings Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Forecast to breakeven in 2025

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance